Summary & Overview
CPT 11981: Insertion of Long-Term Drug-Delivery Implant
CPT code 11981 covers the insertion of a bioresorbable, biodegradable, or non‑biodegradable implant (such as a capsule or pellet) that contains a drug for long‑term delivery. This code defines a procedural category increasingly relevant as sustained‑release implants expand across specialties including oncology, pain management, ophthalmology, and endocrinology. Nationally, accurate coding for device‑based drug delivery affects claims processing, device tracking, and longitudinal therapy management.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context, common sites of service, and how the code is used in practice. The publication summarizes payer coverage patterns and benchmarks where available, highlights relevant policy updates affecting reimbursement and prior authorization, and outlines common billing considerations tied to this procedure type.
The report provides practical reference material for billing and compliance teams, including typical care settings, the clinical rationale for long‑term implants, and points of attention for claims submission. Data not available in the input is identified explicitly where applicable.
Billing Code Overview
CPT code 11981 describes the insertion of a bioresorbable, biodegradable, or non–biodegradable implant (for example, a capsule or pellet) that contains a medication for long‑term drug delivery. The procedure involves placing a drug‑containing implant designed to release medication over an extended period to a targeted site.
-
Service type: Implantation of a drug delivery device for long‑term medication release.
-
Typical site of service: Outpatient procedure settings such as ambulatory surgery centers or hospital outpatient departments; may also be performed in physician offices equipped for minor surgical procedures.
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with hormone-receptor positive breast cancer completed primary therapy and requires long-term endocrine therapy. The oncology team elects subcutaneous insertion of a slow-release endocrine implant (pellet) to provide continuous systemic therapy. The patient is consented in clinic; pre-procedure vital signs and medication reconciliation are completed. The implant is placed in a minor procedure room or ambulatory surgery center under local anesthesia with sterile technique. The provider documents pre-procedure indications, implant device type (bioresorbable or non-biodegradable), drug name and dose, insertion site, procedural steps, any immediate complications, and post-procedure instructions. Typical billing uses 11981 for placement of the drug delivery implant. The procedure may occur in outpatient clinic procedure rooms, ambulatory surgical centers, or hospital outpatient departments depending on patient comorbidity and institutional policy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable E/M service by the same physician on the same day of the procedure | Use when a distinct evaluation and management visit is performed the same day as 11981 and it meets E/M documentation requirements. |